drugset / Trial / NCT03028571

Autonomic Blockade and Endogenous Glucose Production

NCT03028571

RandomizedCrossoverSingle-blindBasic science

Summary

The investigators will test the null hypothesis that there will be no changes in the insulin-mediated suppression of endogenous glucose production (EGP) in response to autonomic blockade. To test this hypothesis, the investigators propose to determine the role of the autonomic nervous system in hepatic insulin resistance.

Timeline

Start
2017-04-17
Primary completion
2022-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Trimethaphan Small molecule 4 mg Intravenous

Indications

No indication recorded.